Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravenous selenium versus magnesium sulfate in severe traumatic brain injury
IRCT20240605062022N1Phase 2Completed
- Sponsor
- Urmia University of Medical Sciences
- Start
- Sep 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of selenium and magnesium sulfate in traumatic brain injury (TBI) (2 arms), sponsored by Urmia University of Medical Sciences. Primary endpoints: Unfavorable versus favorable outcome and Glasgow Outcome Scale. Started Sep 2024; status: completed.
02
Drugs
seleniummagnesium sulfate
03
Conditions
traumatic brain injury (TBI)
Beyond the preview
Go deeper on IRCT20240605062022N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20240605062022N1.